# AI Pancreatic Cancer Tests Bio-AI Company Craif is Seeking Approval for Pancreaschek in Japan By Adam Harrie | Written with AI assistance | Published 2026-09-04 | Tech Source: Trend Hunter, https://www.trendhunter.com/trends/bio-AI References: [mobihealthnews](https://www.mobihealthnews.com/news/asia/nagoya-university-spin-seeks-japan-approval-ai-pancreatic-cancer-test) & [craif](https://craif.com/en)  Craif, a bio-AI spin-off from Nagoya University, is preparing a regulatory filing in Japan for miSignal, a [urine-based AI test](https://www.trendhunter.com/trends/biotiaid-urine-test) designed to detect pancreatic cancer. If approved, the company said it would be the first approved urine-based pancreatic cancer test worldwide. Craif is also preparing to launch miSignal in the U.S. following a $33 million Series D funding round. The test analyzes microRNA in urine using an AI model. In a study published in eClinicalMedicine, the model detected pancreatic cancer across disease stages, including early-stage disease, with sensitivity and specificity exceeding 90%. Craif is expanding R&D at its San Diego laboratory and plans a prospective clinical study to support regulatory and reimbursement requirements in the U.S. For patients and providers, miSignal could offer a non-invasive approach to earlier [pancreatic cancer detection](https://www.trendhunter.com/trends/change-the-course) while supporting broader efforts to [apply AI and molecular diagnostics](https://www.trendhunter.com/trends/cancer-ai-alliance) to difficult-to-detect diseases. Image Credit: Craif ## Trend Insights (Trend Hunter) - Score: 7.5/10 - Popularity: 59% | Activity: 73% | Freshness: 92% - Audience gender: 50% men, 50% women - Primary generations: Millennial, Gen X - Top markets: North America, Asia ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Tech](https://www.trendhunter.com/tech) > [AI](https://www.trendhunter.com/ai) ## Key Themes ### Key Themes Behind This Trend - **Urine-based Cancer Screening:** Non-invasive sample collection creates room for earlier disease detection models that fit routine care and expand access beyond specialized diagnostic settings. - **AI Molecular Diagnostics:** Machine learning applied to microRNA and other biomarkers is reshaping how hard-to-detect cancers are identified before conventional symptoms or imaging findings appear. - **Early-stage Oncology Detection:** High-sensitivity tests for aggressive cancers are opening pathways for preventive oncology programs built around screening, risk stratification, and reimbursable clinical workflows. ### Where This Applies - **Biotechnology:** Bio-AI platforms are creating new value in biomarker discovery by combining molecular science, clinical validation, and software-driven diagnostic interpretation. - **Healthcare Diagnostics:** Laboratories and diagnostic providers face emerging opportunities around scalable, non-invasive cancer testing that supports faster physician decision-making and patient monitoring. - **Digital Health:** AI-enabled test platforms are extending digital health beyond apps into regulated clinical products that connect data science with real-world disease detection. ## Related on Trend Hunter - [Assistive GLP-1 Dining Applications](https://www.trendhunter.com/trends/menuorder-ai.md) - [AI-Powered Menu Companion Apps](https://www.trendhunter.com/trends/menu-order-ai1.md) - [Predictive Cancer AI](https://www.trendhunter.com/trends/Predictive-cancer-AI.md) - [Portable Saliva Cancer Detectors](https://www.trendhunter.com/trends/AI-Enabled-Saliva-Device.md) - [Targeted Tumor Therapy Candidates](https://www.trendhunter.com/trends/human-trial.md) - [Next-Gen Companion Diagnostic Tests](https://www.trendhunter.com/trends/companion-diagnostic-test.md) - [AI-Powered Hepatitis C Programs](https://www.trendhunter.com/trends/The-OpenAI-Foundation.md) - [Cancer Support Tools](https://www.trendhunter.com/trends/icliniq-test.md) - [Early Metastasis Risk Calculators](https://www.trendhunter.com/trends/limpc.md)